The occurrence of amyotrophic lateral sclerosis (ALS) and neuromyelitis optica (NMO) in a single patient is exceedingly rare. We report a case of a 54-year-old woman of East Asian descent with a prior diagnosis of ALS who developed an episode of unexplained hiccups and nausea and vomiting consistent with area postrema syndrome 3 months prior to the onset of acute transverse myelitis. Magnetic resonance imaging revealed abnormal T2 hyperintensity and gadolinium enhancement at the cervicomedullary junction with extension to C3. Imaging was also notable for nonenhancing central cord T2 hyperintensity from T6 to T8 suggesting previous demyelination. The patient's cerebrospinal fluid analysis was mildly inflammatory. She was found to have a positive NMO/aquaporin-4 immunoglobulin G titer (cell-based assay) greater than 1:100 000, consistent with a diagnosis of NMO. The unusual coexistence of ALS and NMO prompts consideration of potential common pathological neuroinflammatory processes.
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of both central and peripheral motor neurons that leads to the eventual loss of voluntary movement. The most recent estimated ALS prevalence is 4 to 5 cases per 100 000 in the United States. 1 The disease affects people of all ethnicities, and the overall survival in affected patients is variable. The diagnosis of ALS is based on the exclusion of alternative causes of signs and symptoms and usually requires progressive upper and lower motor neuron deficits, as recognized by the revised El Escorial Criteria for the diagnosis of ALS. 2 The average survival time from symptom onset is 2 to 5 years, though 10% to 20% of patients with ALS survive beyond 5 years, and a smaller percentage (5%-10%) beyond 10 years. 3 Neuromyelitis optica (NMO) is an inflammatory demyelinating condition with a predilection for the optic nerves and spinal cord. Previously considered a variant of multiple sclerosis (MS), NMO is now recognized as a distinct astrocytopathy associated with serum aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies. 4 The prevalence of NMO ranges from 0.5 to 13 per 100 000, with epidemiological studies suggesting higher rates among East Asian populations. [5] [6] [7] The 2015 international consensus diagnostic criteria for NMO and NMO spectrum disorders recognize 6 core clinical characteristics: optic neuritis, acute myelitis, area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting), acute brain stem syndrome, symptomatic narcolepsy or acute diencephalic clinical syndrome, and symptomatic cerebral syndrome with NMO spectrum disorder-typical brain lesions. 4 The coexistence of ALS and demyelinating disease is exceedingly rare. It has been described in the literature only in the context of MS, suggesting a potential interaction between neuroinflammation and neurodegeneration. 8 To our knowledge, this is the first case report in the literature to describe both ALS and NMO in a patient.
Case Description
At age 43, an East Asian woman presented to neurological care with 3 years of progressive bilateral arm weakness and incoordination. Initial clinical examination was indicative of a slowly progressive lower motor neuron-predominant ALS with mild bulbar weakness, tongue fasciculations, bilateral arm weakness, moderate left leg weakness, absent reflexes in the upper extremities, and 3þ patellar reflexes. Electromyography showed signs of acute and chronic denervation in every sampled muscle of the right arm and hand, spanning spinal segments C5-T1 and 4 peripheral nerve distributions. Positive sharp waves were present in the lower thoracic paraspinal muscles, and fibrillation potentials were observed in the mid-thoracic paraspinal muscles. The patient met the El Escorial diagnostic criteria for clinically probable, laboratory-supported ALS with upper motor neuron signs in the lumbosacral region and clinical and electromyographysupported lower motor neuron signs in bulbar and cervical regions. Brain and spine magnetic resonance imaging (MRI) did not reveal an alternative diagnosis. The patient experienced progressive dysarthria and dysphagia leading to placement of a percutaneous endoscopic gastrostomy tube at age 49. She had worsening respiratory failure and became ventilator dependent with a tracheostomy by age 50.
At age 54, she presented to a community hospital with the acute onset of intractable nausea, vomiting, and hiccups. Her symptoms were initially attributed to gastroparesis or gastroenteritis, but all studies were negative. Three months later, she presented to our institution with progressively worsening symmetric paresthesias involving the arms, legs, and lower trunk. She had painful paroxysmal leg spasms triggered by leg movement and neck flexion. She developed a new right foot drop and reduced right-hand dexterity compared to her baseline weakness from ALS. Her weakness from ALS prior to presentation included severe bilateral proximal arm weakness at 0/5 in her deltoids and 2/5 in her triceps and biceps with retained right-hand dexterity as evidenced by her ability to use her smartphone. Her baseline lower extremity weakness from ALS was less affected with 4/5 bilateral lower extremity strength including dorsiflexion. She also had a baseline normal sensory examination. Her new examination, on the other hand, was notable for decreased sensation to pinprick below the T6 dermatome. Careful history revealed no prior optic neuritis or myelitis episodes.
Spine MRI revealed a gadolinium-enhancing, right lateral T2 hyperintense lesion extending from the cervicomedullary junction to C3. There was also a nonenhancing central cord T2 hyperintensity from T6 to T8, suggesting previous demyelination ( Figure 1 ). Brain MRI revealed 2 small, gadoliniumenhancing, T2 hyperintense lesions in the posterior body of the corpus callosum and wall of the right lateral ventricle with associated restricted diffusion (Figure 2) .
Cerebrospinal fluid analysis revealed a lymphocytic pleocytosis of 42/mL (reference: 0-5/mL) with mildly elevated protein of 58 mg/dL (reference: <45 mg/dL) but normal IgG index of 0.45 (reference: <0.70) and an absence of oligoclonal bands. Serum AQP4-IgG cell-based assay returned positive with an elevated titer of greater than 1:100 000 (reference: <1:5 titer). A diagnosis of NMO was made based on international consensus criteria. 4 Steroids were administered for acute treatment, and rituximab was initiated for prevention of future NMO exacerbations.
Discussion
We report the unusual case of a patient with long-standing ALS who developed transverse myelitis and met diagnostic criteria for NMO. In this case, the patient developed signs and symptoms of ALS long prior to her presentation and subsequent diagnosis with NMO. Although we acknowledge that harm to neighboring anterior horn cells could be a sequelae from prior episodes of myelitis and mimic ALS lower motor neuron findings, the time course of the patient's earliest symptoms of slowly progressive upper limb weakness and bulbar dysfunction argue against this. In addition, her MRI imaging did not show old, nonenhancing lesions that would localize to these earliest symptoms. We found no evidence of prior inflammation in the brain stem or cervical spinal cord, but rather only new enhancing lesions. Therefore, while our patient's new development of NMO may represent an unfortunate coincidence, shared pathological mechanisms must be considered.
The coexistence of ALS and an inflammatory demyelinating disease has been described previously only in the context of MS, suggesting that ALS and MS may share patterns of neuroinflammation, specifically signaling pathways and bloodbrain barrier disruption. 8 Activated transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NK-kB) was found in both oligodendrocytes of active MS plaques and astrocytes, but not motor neurons, of patients with ALS. 9, 10 Similar neuroinflammatory mechanisms may exist in NMO pathogenesis. In a 2015 analysis of autopsy-derived central nervous system (CNS) tissue, astroglial cultures stimulated with IgG isolated from patients with NMO elicited an astrocytic NF-kB-dependent inflammatory response which was not seen with IgG from healthy controls. 11 These findings suggest that an astrocytic inflammatory response to AQP4-IgG may be an early pathogenic event in NMO.
Amyotrophic lateral sclerosis rodent models also indicate alterations in AQP4 expression and blood-brain barrier integrity that may contribute to the coexistence of NMO. First, these ALS models show an overexpression of AQP4 mRNA and protein in spinal cord gray matter with increased AQP4 immunoreactivity localizing to swollen perivascular astrocytes. 12 Second, these ALS rodents exhibit impaired blood-brain and blood-spinal cord barriers with increased neurovascular permeability. 13 Postmortem studies of patients with sporadic ALS show similar barrier disruption.
14 This leaky blood-CNS barrier may allow substantial influx of the AQP4-IgG antibody and access to the overexpressed AQP4 water channel contributing to the development of NMO. Entry of peripherally circulating AQP4-IgG into the CNS may also occur via circumventricular organs that lack a blood-CNS barrier and are AQP4 enriched. 15 The possibility of shared pathologic neuroinflammatory mechanisms in ALS and NMO warrants further study.
